NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week was full of exciting news. The KPHC rose 2.2% compared to 0.5% for the Danish healthcare stocks. Acarix received a new multi-unit order, Zealand Pharma raised DKK 7 billion, Genmab got a new FDA approval, Gubra initiated clinical development together with Boehringer Ingelheim, and new higher price targets.

10 of the 22 Danish healthcare companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with a 291% return and PolarCool was the best Nordic healthcare investment last week. 4 Danish healthcare stocks with +100% YTD return.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

Acarix Secures Multi-Unit Order from In-Home Concierge Practice (Link)

Ascendis Pharma

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCBH 2024 (Link)

Biosergen

No news the past week

Cessatech

Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001 (Link)

CS Medica

CEO Insights on Achievements and Future Plans (Link)

Curasight

No news the past week

DanCann Pharma

DanCann Pharma A/S announces outcome of the Rights Issue (Link)

Evaxion Biotech

Evaxion Receives Positive Feedback on Patent Application for AI-Based Novel Cancer Vaccine Target Identification Method (Link)

ExpreS2ion

ExpreS2ion Biotechnologies: ExpreS2ion announces poster presentation on the use of glycoengineered Drosophila S2 cells for production of highly immunogenic antigens at the ESACT meeting (Link)

Fluoguide

No news the past week

Genmab

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma (Link)

TEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (Link)

Gubra

A board member of Gubra bought shares for almost DKK 150,000.

Boehringer Ingelheim and Gubra announce start of clinical development of a potential first-in-class, triple agonist, obesity treatment (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

Pila Pharma sponsors international diabetes & nutrition conference (Link)

Saniona

No news the past week

Scandion Oncology

SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE (Link)

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion (Link)

Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion (Link)

Zealand Pharma got several new price targets set in the past week. Danske Bank raised to DKK 800 (625), SEB to DKK 990 (805), and Jeffries to DKK 1100 (790).

Y-mAbs Therapeutics

No news the past week

2cureX

Annual report 2023 (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance the past week of 0.5% compared to 2.2% for the KPHC index. Acarix became the winner with a 18% price increase following a new multi-unit order. Zealand Pharma had another week of stellar performance with a capital raise of DKK 7 billion as well as higher price targets being set by Danske Bank, SEB, and Jeffries. Genmab also got TEPKINLY approved by the FDA in the U.S. for patients with relapsed or refractory (R/R) follicular lymphoma although the stock ended the week with a small price decrease. Finally, a board member at Gubra bought shares and they also announced the start of clinical development for an obesity treatment together with Boehringer Ingelheim.

The best stock year-to-date is Gubra followed by Pila Pharma with 169 and 291% increases after the first 6 months of trading. Zealand Pharma and Acarix have also made a +100% return year-to-date. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 18.4%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) rose 2.2% to 67,84. The index has had a strong performance since the end of April, but last week the index took a hit. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 7%.

The index development for Kapital Partner Healthcare Index the past 12 months

39-84% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

PolarCool AB (84%)  is focused on offering products and solutions targeted at injuries in sports and physical activity. Main focus is on research and development of products used for the treatment of various brain injuries, for example in boxing, rugby, and American football. PolarCool rose after a successful capital raise with over 100% of shares subscribed.

Brain+ A/S (52%) specialises in research and development for the treatment of dementia and Alzheimer’s. The product portfolio includes, for example, Cognitive Stimulation Therapy. Brain+ rose following a capital raise with 66.6% shares being subscribed.

Respiratorius AB (39%) is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. Respiratorius also did a capital raise with 50% of shares being subscribed.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites